Dr. Daniel DeAngelo, MD, PhD
Claim this profileDana Farber Cancer Institute
Studies Childhood Cancer
Studies Granulocytic Leukemia
9 reported clinical trials
11 drugs studied
Area of expertise
1Childhood Cancer
Philadelphia chromosome negative
CD123 positive
2Granulocytic Leukemia
CD123 positive
Affiliated Hospitals
Clinical Trials Daniel DeAngelo, MD, PhD is currently running
Venetoclax + Chemotherapy
for Leukemia
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine
Recruiting3 awards Phase 1 & 2
Avapritinib + Decitabine
for Systemic Mastocytosis
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.
Recruiting1 award Phase 1
More about Daniel DeAngelo, MD, PhD
Clinical Trial Related7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daniel DeAngelo, MD, PhD has experience with
- Venetoclax
- Azacitidine
- Avapritinib
- IMGN632
- Standard Chemotherapy
- Calaspargase Pegol
Breakdown of trials Daniel DeAngelo, MD, PhD has run
Childhood Cancer
Granulocytic Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel DeAngelo, MD, PhD specialize in?
Daniel DeAngelo, MD, PhD focuses on Childhood Cancer and Granulocytic Leukemia. In particular, much of their work with Childhood Cancer has involved Philadelphia chromosome negative patients, or patients who are CD123 positive.
Is Daniel DeAngelo, MD, PhD currently recruiting for clinical trials?
Yes, Daniel DeAngelo, MD, PhD is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Daniel DeAngelo, MD, PhD has studied deeply?
Yes, Daniel DeAngelo, MD, PhD has studied treatments such as Venetoclax, Azacitidine, Avapritinib.
What is the best way to schedule an appointment with Daniel DeAngelo, MD, PhD?
Apply for one of the trials that Daniel DeAngelo, MD, PhD is conducting.
What is the office address of Daniel DeAngelo, MD, PhD?
The office of Daniel DeAngelo, MD, PhD is located at: Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.